Drug intelligence / Profile preview

GB19

Development stage: Preclinical
Lead developer: Kexing
Modality: Small Molecules

Overview

GB19 is a novel small molecule identified as a potent inhibitor of Dipeptidyl Peptidase IV (DPP4). Molecular docking and dynamics simulations suggest it has a high binding affinity towards the DPP4 active site through conventional hydrogen bonding and hydrophobic interactions. It is being investigated for its potential in the discovery of new drugs to treat type 2 diabetes. The identifier "GB19" is non-specific and also refers to a mouse monoclonal antibody that binds to the human transferrin receptor, produced against full-term human placental microvilli.

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on GB19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB19.

Explore the full profile